<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260615069812N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-05</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Calcium Gluconate drip treatment in pediatrics with normal calcium level after cardiac surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Calcium Gluconate drip treatment in pediatrics with normal calcium level after cardiac surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-06-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91010</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: Group 1 (Hypocalcemic Group):
Patients with hypocalcemia will receive intravenous calcium gluconate infusion at a dose of 1 mg/kg/hour. The infusion will be continued until the serum calcium level reaches the normal range, defined as at least 8.5 mg/dL.
Group 2 (Normocalcemic Group):
Children with normal serum calcium levels will receive intravenous calcium gluconate infusion at a dose of 0.5 mg/kg/hour. The infusion will be continued until the serum calcium level reaches the upper normal limit of 10.5 mg/dL, after which the infusion will be discontinued, Blinding description: This study will be conducted using a double-blind design, whereby neither the investigators nor the parents/legal guardians will be aware of the treatment allocation. To maintain blinding, calcium gluconate infusions and placebo (normal saline) infusions will be prepared and administered in an identical manner.</study_design>
      <phase>3</phase>
      <hc_freetext>Children undergoing cardiac surgery.</hc_freetext>
      <i_freetext>Intervention group: Group 1 consists of patients with hypocalcemia who receive intravenous calcium gluconate treatment. The dose of calcium gluconate in this group is 1 mg/kg/hour administered as an intravenous drip until the serum calcium level reaches at least the normal range (≥ 8.5 mg/dL). In Group 2, children with normal serum calcium levels receive a calcium gluconate infusion at a dose of 0.5 mg/kg/hour. The infusion is continued until the serum calcium level reaches a higher target (&gt; 10.5 mg/dL), after which the infusion is discontinued..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data and study-related documents will be shared only after all personal identifiers and confidential information have been removed. De-identified data may be made available to qualified researchers upon reasonable request and with approval from the principal investigator, solely for scientific and research purposes. Data sharing will be conducted through secure electronic transfer or by depositing the data in an appropriate research data repository, where applicable. The study protocol, data collection instruments, and other relevant study documents may also be shared upon request, provided that confidentiality and ethical requirements are fully maintained. All data sharing will be carried out in accordance with applicable research ethics guidelines and data protection regulations.

When:
Data will be available upon completion of data collection

To whom:
Principal Investigator, study team members, and qualified researchers upon reasonable request and approval

Conditions:
For scientific and research purposes only, subject to confidentiality requirements and approval by the Principal Investigator.

Where to obtain:
The Principal Investigator of the study ( email)

How to obtain:
Data/document access requests will be reviewed by the Principal Investigator. Access will be granted after approval of the request and confirmation of compliance with confidentiality and research ethics requirements.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>maryam zeinali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>saadat abad , modarres hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1998734383</zip>
        <telephone>+98 21 2208 3095</telephone>
        <email>maryamzeinali@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>maryam zeinali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Saadat abad , Modarres hospial</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1998734383</zip>
        <telephone>+98 21 2208 3095</telephone>
        <email>maryamzeinali@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age ≤ 18 years
Hospitalization for cardiac surgery-related disease
Availability of documented serum calcium level measurements</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>19 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of underlying metabolic or endocrine disorders
Severe non-cardiac medical illness
Refusal of participation by the patient or parent/legal guardian
Development of severe adverse events during the study
History of hypersensitivity to calcium gluconate</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Q20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Congenital malformations of cardiac chambers and connections</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group 1 consists of patients with hypocalcemia who receive intravenous calcium gluconate treatment. The dose of calcium gluconate in this group is 1 mg/kg/hour administered as an intravenous drip until the serum calcium level reaches at least the normal range (≥ 8.5 mg/dL). In Group 2, children with normal serum calcium levels receive a calcium gluconate infusion at a dose of 0.5 mg/kg/hour. The infusion is continued until the serum calcium level reaches a higher target (&gt; 10.5 mg/dL), after which the infusion is discontinued.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Calcium level, duration of ICU and hospital stay, duration of intubation, and the degree of inotrope requirement. Timepoint: Serum calcium levels in children are measured at specific time points (before the start of treatment, during the course of treatment, and after completion of treatment). Method of measurement: Medical record.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-27</approval_date>
        <contact_name>Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Modarres Hospital, Yadegar-e-Emam Highway, Saadat Abad intersection, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
